Nizoral Cream

/ Janssen

Cutaneous candidosis, tinea corporis, tinea cruris, tinea manus, tinea pedis and tinea (pityriasis) versicolor: it is recommended that this Cream be applied once or twice daily to cover the affected and immediate surrounding area.
The usual duration of treatment is: tinea versicolor 2-3 weeks, yeast infections 2-3 weeks, tinea cruris 2-4 weeks, tinea corporis 3-4 weeks, tinea pedis 4-6 weeks.
Seborrhoeic dermatitis: this Cream should be applied to the affected area once or twice daily. The usual initial duration of treatment in seborrhoeic dermatitis is 2 to 4 weeks. Maintenance therapy can be applied intermittently (once weekly) in seborrhoeic dermatitis.
Treatment should be continued until a few days after disappearance of all symptoms. The diagnosis should be reconsidered if no clinical improvement is noted after 4 weeks of treatment. General measures in regard to hygiene should be observed to control sources of infection or reinfection.
Seborrhoeic dermatitis is a chronic condition and relapse is highly likely.

Treatment of dermatophyte infections of the skin: such as tinea corporis, tinea cruris, tinea manus and tinea pedis infections due to Trichophyton spp, Microsporom spp and Epidermophyton spp.
This cream is also indicated for the treatment of cutaneous candidosis (including vulvitis), tinea (pityriasis) versicolor and seborrhoeic dermatitis caused by Malassezia (previously called Pityrosporum) spp.

This cream is contraindicated in individuals with a known hypersensitivity to any of its ingredients.

This cream is not for ophthalmic use.
To prevent a rebound effect after stopping a prolonged treatment with topical corticosteroids it is recommended to continue applying a mild topical corticosteroid in the morning and to apply this Cream in the evening, and to subsequently and gradually withdraw the steroid therapy over a period of 2-3 weeks.

Common: Skin burning sensation, Application site erythema, and Application site pruritus.
See prescribing information for full details.

No interaction studies have been performed.

There are no adequate and well-controlled studies in pregnant or lactating women. Plasma concentrations of ketoconazole are not detectable after topical application of this cream to the skin of non-pregnant humans. There are no known risks associated with the use of this cream in pregnancy or lactation.

Topical Applicatiopn: Excessive topical application may lead to erythema, oedema and a burning sensation, which will disappear upon discontinuation of the treatment.
Ingestion: In the event of accidental ingestion, supportive and symptomatic measures should be carried out.